<item>
  <date>2015-05-6</date>
  <hash>5e4f94ef64ba0c28bb4d83a84e39e2da8ad1297d</hash>
  <images></images>
  <index>1</index>
  <keywords>
    <name>Alexion Pharmaceuticals</name>
    <index>1</index>
    <slug>/wiki/alexion%20pharmaceuticals</slug>
  </keywords>
  <keywords>
    <name>Synageva BioPharma</name>
    <index>13</index>
    <slug>/wiki/synageva%20biopharma</slug>
  </keywords>
  <keywords_list>Alexion Pharmaceuticals</keywords_list>
  <keywords_list>Synageva BioPharma</keywords_list>
  <keywords_main>Alexion Pharmaceuticals</keywords_main>
  <slug>/feed/2015/05/6/alexion-pharmaceuticals-agrees-to-purchase-synageva-biopharma-a-maker-of-rare-disease-treatments-for-us-86-billion</slug>
  <sources>
    <name>New York Times</name>
    <day>6</day>
    <hash>29bc0bac2efc26065458498ab893ba4ad2ad2641</hash>
    <month>5</month>
    <permalink>https://www.nytimes.com/2015/05/07/business/dealbook/alexion-puts-its-soaring-stock-price-to-good-use.html</permalink>
    <year>2015</year>
  </sources>
  <text>Alexion Pharmaceuticals agrees to purchase Synageva BioPharma, a maker of rare disease treatments, for US$8.6 billion. </text>
</item>
